Freeline Announces $26.1 Million Registered Direct Offering of American Depositary Shares
March 10, 2022 21:16 ET
|
Freeline Therapeutics
LONDON, March 11, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline Announces First Patient Dosed in the Phase 1/2 B-LIEVE Dose-Confirmation Trial in Hemophilia B
March 09, 2022 07:44 ET
|
Freeline Therapeutics
On track to complete dosing of the first cohort and share initial data by the end of the first half of 2022 On track to start pivotal Phase 3 trial in 2023 LONDON, March 09, 2022 (GLOBE NEWSWIRE)...
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 06, 2022 16:01 ET
|
Freeline Therapeutics
LONDON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1
January 06, 2022 07:00 ET
|
Freeline Therapeutics
FLT201 is the first AAV gene therapy program to enter the clinic for Gaucher disease Type 1 FLT201 Phase 1/2 trial for Gaucher disease Type 1 on track for patient dosing in the first half of 2022 ...
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2021 16:01 ET
|
Freeline Therapeutics
LONDON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline to Participate in Evercore ISI 4th Annual HealthCONx Conference
November 23, 2021 16:01 ET
|
Freeline Therapeutics
LONDON, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline to Participate in Stifel 2021 Virtual Healthcare Conference
November 10, 2021 16:01 ET
|
Freeline Therapeutics
LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline Reports New Data from Fabry Disease Program, Pipeline and Company Updates, Including Appointment of Pamela Foulds, MD as Chief Medical Officer, and Third Quarter 2021 Financial Results
November 09, 2021 16:01 ET
|
Freeline Therapeutics
Lowest dose cohort of MARVEL-1 trial of FLT190 for Fabry disease demonstrates durable α-Gal A expression over two years in the first patient and promising efficacy with near normal α-Gal A levels in...
Freeline Announces Orphan Drug Designations for FLT201 for the Treatment of Gaucher Disease
September 09, 2021 07:00 ET
|
Freeline Therapeutics
LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline to Participate in Upcoming Investor Conferences in September 2021
September 07, 2021 07:00 ET
|
Freeline Therapeutics
LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...